Jump to content

Tercica

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by GünniX (talk | contribs) at 05:48, 2 July 2018 (Template fixed). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency (Primary IGFD), which is characterized by growth faiulre, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.

Tercica licensed rights to develop, manufacture, and market Increlex from Genentech, Inc. Increlex conducted Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with Primary IGFD.

In 2008, the Ipsen Group acquired Tercica and changed its name to Ipsen Biopharmaceuticals, Inc.[1]

See also

References

  1. ^ "Ipsen buys Tercica for $404 million". www.bizjournals.com. Retrieved 2018-06-22.
Stub icon

This biotechnology article is a stub. You can help Wikipedia by expanding it.

Stub icon

This United States corporation or company article is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tercica&oldid=848483725"